StarkAge Therapeutics has announced the upcoming presentation of preclinical data on STX-1, a first-in-class senolytic antibody-drug conjugate (ADC) targeting DPP4, at the AACR Annual Meeting 2026. This innovative therapy aims to address the challenges of therapy-induced senescence, a significant contributor to tumor progression and treatment resistance, particularly in solid tumors. The presentations will highlight STX-1’s mechanism of selectively eliminating DPP4-expressing cells in both tumor and stromal environments, offering a promising therapeutic avenue for patients with limited options.

The significance of this research lies in its focus on treatment-induced senescence as a pivotal factor in metastatic colorectal cancer. StarkAge, in collaboration with the Gustave Roussy Institute, will present findings that characterize DPP4 as a senescence-associated biomarker. Utilizing advanced techniques such as immunohistochemistry and single-cell RNA sequencing, the study elucidates the relationship between senescence-related biology and its implications for disease progression and resistance to existing therapies. Notably, the preclinical data demonstrate that STX-1 exhibits strong affinity and target-dependent cytotoxicity, particularly in senescent cell-enriched tumors, indicating its potential to overcome current therapeutic limitations.

The concrete implication of these findings is the potential shift in clinical strategies for treating solid tumors. By establishing STX-1 as a dual-action agent that combines anticancer and senolytic properties, this research could redefine treatment paradigms and expedite drug development timelines for senescence-targeted therapies. As STX-1 progresses toward IND-enabling studies, it may pave the way for novel interventions that address both tumor biology and the senescence landscape, ultimately enhancing patient outcomes in oncology.

Source: globenewswire.com